ENDPOINTS

Marea heads to Phase 2b after updated biomarker data show CV drug’s promise

Marea Therapeutics said on Wednesday that its lipid-lowering antibody cut both remnant cholesterol levels and remnant triglycerides — both indicators for cardiovascular disease in at-risk patients. The highest dose tested in the Phase 2a trial of ...

May 7, 2025 - 11:03
 0
Marea heads to Phase 2b after updated biomarker data show CV drug’s promise
Marea Therapeutics said on Wednesday that its lipid-lowering antibody cut both remnant cholesterol levels and remnant triglycerides — both indicators for cardiovascular disease in at-risk patients. The highest dose tested in the Phase 2a trial of ...
Read More

Tags:

Previous Article

The sustainability community has fumbled the ball. It’s time for a reset

Next Article

EVs Take 63.3% Share In Sweden – Renault 5 Starts Climbing

Related Posts

As the XBI suffers, Q1 shows a few comforting signs of underlying stability

As the XBI suffers, Q1 shows a few comforting signs of ...

Apr 22, 2025  0

Function buys Ezra, combining preventive testing and scans

Function buys Ezra, combining preventive testing and scans

May 5, 2025  0

AbbVie eyes $10B US expansion amid sector-specific tariff threat

AbbVie eyes $10B US expansion amid sector-specific tari...

Apr 25, 2025  0